Our experience with transanal total mesorectal excision (TaTME) procedures in middle and distal rectal tumors

Česká verze

Authors: V. Procházka ¹ ; T. Grolich ¹; M. Farkašová ¹; V. Čan ¹; R. Svatoň ¹; M. Svoboda ²; L. Ostřížková ³; M. Eid ³; L. Frola ⁴; Š. Bohatá ⁵; Z. Kala ¹
Authors place of work: Chirurgická klinika Fakultní nemocnice Brno a Lékařské fakulty Masarykovy univerzity v Brně ¹; Lékařská fakulta Masarykovy Univerzity v Brně ²; Interní hematologická a onkologická klinika Fakultní nemocnice Brno a Lékařské fakulty Masarykovy univerzity v Brně ³; Ústav patologie Fakultní nemocnice Brno a Lékařské fakulty Masarykovy univerzity v Brně ⁴; Klinika radiologie a nukleární medicíny Fakultní nemocnice Brno a Lékařské fakulty Masarykovy univerzity v Brně ⁵
Published in the journal: Rozhl. Chir., 2020, roč. 99, č. 3, s. 124-130.
Category: Původní práce
doi: https://doi.org/10.33699/PIS.2020.99.3.124–130

Summary

Introduction: Transanal total mesorectal excision (TaTME) is a relatively new approach in surgical treatment of rectal cancer. There are no clear indications when to choose this strategy. It is a technically demanding procedure for the surgeon with a long learning curve, which should also be taken into account in evaluation of this method. The results of both oncological and postoperative complications must be properly evaluated to explore the benefit of TaTME. The aim of this study is to assess the potential benefit of TaTME compared to other alternatives in middle and distal rectal tumors.

Methods: Retrospective evaluation of patients undergoing TaTME procedure performed by one team of surgeons between October 2014 and June 2019. The authors analyzed demographic indicators of the group of patients, tumor characteristics, specimen quality, early postoperative complications and the possibility of stoma reversal.

Results: A total of 93 patients underwent TaTME procedure for middle and distal rectal cancer. Mean BMI was 27.6 (4.8). T3 or T4 tumor was found in 73 (78.5%) patients, 68 (73.1%) patients had positive lymph nodes and 12 (12.9%) patients were treated for synchronous metastatic rectal cancer. Neoadjuvant therapy was used in 80 (86%) patients. Conversion to open laparotomy was necessary in one case (1%). Stapled anastomosis was performed in 37 (39.7%) cases, handsewn in 56 (60.2%). A positive circumferential resection margin (CRM) was found in 10 (10.7%) cases. Distal resection margin (DRM) was positive in 3 (3.2%) patients. Pathological analysis showed a complete mesorectum in 18 patients (19.4%), nearly complete in 39 (41.9%) and an incomplete mesorectum in 36 (38.7%). Complications in the first 30 days after primary surgery were observed in 38 (40.8%) patients, mainly for anastomotic leak (19 patients, 20.4%). Reoperation was required in 7 (7.5%) patients. Permanent colostomy had to be performed in 4 (4.3%) cases. No patient died after surgery.

Conclusion: In a selected group of patients it is possible to perform resection using this approach with acceptable postoperative morbidity and quality of the specimen. We used TaTME procedure in patients expected to have difficult TME due to obesity, size and distal localization of tumor. The incidence of conversion to open surgery was very low. Further studies for long term oncological outcomes are needed.

Keywords:

complications – rectal cancer – transanal total mesorectal excision – circumferential resection margin

Zdroje

Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1986;1:1479–1482. doi:10.1016/s0140-6736(86)91510-2.
Quirke P, Durdey P, Dixon MF, Williams NS. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumor spread and surgical excision. Lancet 1986;2:996–999. doi:10.1016/s0140-6736(86)92612-7.
Vennix S, Pelzers L, Bouvy N, et al. Laparoscopic versus open total mesorectal excision for rectal cancer. Cochrane Database of Systematic Reviews 2014;4:CD005200. doi:10.1002/14651858.CD005200.pub3.
Bonjer HJ, Deijen CL, Abis GE, et al. COLOR II Study Group. A randomized trial of laparoscopic versus open surgery for rectal cancer. N Engl J Med 2015;372:1324–1332. doi:10.1056/NEJMoa1414882.
Rullier E, Zerbib F, Laurent C, et al. Intersphincteric resection with excision of internal anal sphincter for conservative treatment of very low rectal cancer. Dis Colon Rectum 1999;42:1168–1175. doi:10.1007/bf02238569.
Marks JH, Salem JF. From TATA to NOTES, how taTME fits into the evolutionary surgical tree. Tech Coloproctol. 2016;20:513–515. doi:10.1007/s10151-016-1504-9.
Lacy AM, Tasende MM, Delgado S, et al. Transanal total mesorectal excision for rectal cancer: outcomes after 140 patients. J Am Coll Surg. 2015;221:415–423. doi:10.1016/j.jamcollsurg.2015.03.046.
Larsen SG, Pfeffer F, Kørner H; Norwegian Colorectal Cancer Group. Norwegian moratorium on transanal total mesorectal excision. Br J Surg. 2019;106:1120–1121. doi:doi.org/10.1002/bjs.11287.
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–213. doi:10.1097/01.sla.0000133083.54934.ae.
Quirke P, Durdey P, Dixon MF, et al. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision. Lancet 1986;2:996–999. doi:10.1016/s0140-6736(86)92612-7.
Perdawood SK, Thinggaard BS, Bjoern MX. Effect of transanal total mesorectal excision for rectal cancer: comparison of short-term outcomes with laparoscopic and open surgeries. Surg Endosc. 2018;32:2632–2642. doi:10.1007/s00464-017-5926-x.
Xu W, Xu Z, Cheng H, et al. Comparison of short-term clinical outcomes between transanal and laparoscopic total mesorectal excision for the treatment of mid and low rectal cancer: A meta-analysis. Eur J Surg Oncol. 2016;42:1841–1850. doi:10.1016/j.ejso.2016.09.002.
Jiang HP, Li Ys, Wang B, et al. Pathological outcomes of transanal versus laparoscopic total mesorectal excision for rectal cancer: a systematic review with meta-analysis. Surg Endosc. 2018;32:2632–2642. doi:10.1007/s00464-018-6103-6.
Veltcamp Helbach M, Koedam TWA, et al. Residual mesorectum on postoperative magnetic resonance imaging following transanal total mesorectal excision (TaTME) and laparoscopic total mesorectal excision (LapTaTME) in rectal cancer. Surg Endosc. 2019;33:94–102. doi:10.1007/s00464-018-6279-9.
Chen YI, Kiu KT, Chang TC. Comparison of the short-term outcomes in lower rectal cancer using three different surgical techniques: Transanal total mesorectal excision (TME), laparoscopic TME, and open TME. Asian J Surg. 2019;42:674–680. doi:10.1016/j.asjsur.2018.09.008.
Detering R, Roodbeen SX, van Oostendorp SE, et al. Three year nationwide experience with transanal total mesorectal excision for rectal cancer in the Netherlands: A propensity score-matched comparison with conventional laparoscopic total mesorectal excision. J Am Coll Surg. 2019;228:235–244. doi:10.1016/j.jamcollsurg.2018.12.016.
Bryant CL, Lunniss PJ, Knowles CH, et al. Anterior resection syndrome. Lancet Oncol. 2012;13:e403–408. doi:10.1016/S1470-2045(12)70236-X.
Chen CC, Lai YL, Jiang JK, et l. Transanal total mesorectal excision versus laparoscopic surgery for rectal cancer receiving neoadjuvant chemoradiation: a matched case-control study. Ann Surg Oncol. 2016;23:1169–1176. doi:10.1245/s10434-015-4997-y.
Penna M, Hompes R, Arnold S, et al. Incidence and risk factors for anastomotic failure in 1594 patients treated by transanal total mesorectal excision: Results from the International TaTME Registry. Ann Surg. 2018;269:700–711. doi:10.1097/SLA.0000000000002653.
Celentano V, Cohen R, Warusavitarne J, et al. Sexual dysfunction following rectal cancer surgery. Int J Colorectal Dis. 2017;32:1523–1530. doi:10.1007/s00384-017-2826-4.
Chouillard E, Regnier A, Vitte RL, et al. Transanal NOTES total mesorectal excision (TME) in patients with rectal cancer: is anatomy better preserved? Tech Coloproctol. 2016;20:537–44. doi:10.1007/s10151-016-1449-z.
Koedam TWA, van Ramshorst GH, Deijen CL, et al. Transanal total mesorectal excision (TaTME) for rectal cancer: effects on patient-reported quality of life and functional outcome. Tech coloproctol. 2017;21:25–33. doi: 10.1007/s10151-016-1570-z.
Allaix ME, Furnée EJ, Mistrangelo M, et al. Conversion of laparoscopic colorectal resection for cancer: What is the impact on short-term outcomes and survival? World J Gastroenterol. 2016;22:8304–8313. doi:10.3748/wjg.v22.i37.8304.
Ki Young Lee, Jung Kyoung Shin, Yoon Ah Park, et al. Transanal endoscopic and transabdominal robotic total mesorectal excision for mid-to-low rectal cancer: Comparison of short-term postoperative and oncologic outcomes by using a case-matched analysis. Ann Coloproctol. 2018;34: 29–35. doi: 10.3393/ac.2018.34.1.29.
Hain E, Maggiori L, Manceau G, et al. Persistent asymptomatic anastomotic leakage after laparoscopic sphincter-saving surgery for rectal cancer: can diverting stoma be reversed safely at 6 months? Dis Colon Rectum 2016;59:369–376. doi:10.1097/DCR.0000000000000568.
Ito M, Sugito M, Kobayashi A, et al. Relationship between multiple numbers of stapler firings during rectal division and anastomotic leakage after laparoscopic rectal resection. Int J Colorectal Dis. 2008;23:703–707. doi:10.1007/s00384-008-0470-8.
Kasalický M, Martínek L, Penka I. Je laparoskopická kolorektální chirurgie bezpečná i u starších pacientů? Rozhl Chir. 2018;97:21–26.
Person B, Vivas DA, Wexner SD. Totally laparoscopic low anterior resection with transperineal handsewn colonic J-pouch anal anastomosis for low rectal cancer. Surg Endosc. 2006;20:700–702. doi:10.1007/s00464-005-0581-z.
Hu JH, Li XW, Wang CY, et al. Short-term efficacy of natural orifice specimen extraction surgery for low rectal cancer. World J Clin Cases 2019;26:122–129. doi:10.12998/wjcc.v7.i2.122.
Constantino FA, Diana M, Wall J, et al. Prospective evaluation of peritoneal fluid contamination following transabdominal vs. transanal specimen extraction in laparoscopic left-sided colorectal resection. Surg Endosc. 2012;26:1495–1500. doi: 10.1007/s00464-011-2066-6.
Hol JC, van Oostendorp SE, Tuynman JB, et al. Long-term oncological results after transanal total mesorectal excision for rectal carcinoma. Tech Coloproctol 2019;23:903-911. doi: https://doi.org/10.1007/s10151-019-02094-8.
Izquierdo KM, Unal E, Marks JH. Natural orifice specimen extraction in colorectal surgery: patient selection and perspectives. Clinical and Experimental Gastroenterology 2018;11:265–279. doi:10.2147/CEG.S135331.
International TaTME Registry [Internet] 2014. Available from: www.tatme.surgery.
Adamina M, Buchs NC, Penna M, et al. St. Gallen Colorectal Consensus Expert Group. St. Gallen consensus on safe implementation of transanal total mesorectal excision. Surg Endosc. 2018;32:1091–1103. doi:10.1007/s00464-017-5990-2.